The six drugs on the agenda for the US House Committee on Oversight and Reform’s upcoming drug price hearing are all older mature medicines, some of which are already available as generics. Generally, the products have been or were at one time the bread and butter for their respective drug makers and grew over time into blockbusters through regular annual or even biannual price increases, a practice that has come under more scrutiny in recent years.
The Congressional committee announced the hearing on 22 September and revealed six pharmaceutical industry leaders who have been called to testify at the hearing, along with the brands they’ll represent....
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
